Insmed, Inc. (NASDAQ:INSM)

CAPS Rating: 3 out of 5

Insmed Incorporated, a biopharmaceutical company, is focused on developing and commercializing novel, targeted inhalation therapies.

Results 1 - 13 of 13

Recs

0
Member Avatar TMFTypeoh (75.43) Submitted: 10/12/2015 9:43:18 PM : Outperform Start Price: $13.87 INSM Score: -18.71

Interesting company

Recs

1
Member Avatar scrubs62074 (< 20) Submitted: 2/12/2013 2:56:15 PM : Outperform Start Price: $6.07 INSM Score: +47.01

High Volume Breakout on 02/12/13

Recs

2
Member Avatar solanZRaider (< 20) Submitted: 6/26/2012 4:07:27 PM : Outperform Start Price: $3.18 INSM Score: +192.14

ZZ Top

Recs

0
Member Avatar nvcrader (42.82) Submitted: 1/21/2012 2:49:47 AM : Outperform Start Price: $5.03 INSM Score: +63.50

UPDATE 2-FDA lifts hold on Insmed's lung disease drug, shares jump

Recs

0
Member Avatar justinjohngalt (< 20) Submitted: 7/15/2010 1:20:05 PM : Outperform Start Price: $6.84 INSM Score: -26.32

Cash

Recs

0
Member Avatar mhurdle (< 20) Submitted: 6/21/2009 9:24:46 PM : Outperform Start Price: $24.70 INSM Score: -181.19

attractive economics; strong product

Recs

0
Member Avatar BeatBuffet (41.12) Submitted: 6/12/2009 9:42:06 AM : Outperform Start Price: $21.30 INSM Score: -167.52

Because people eat and drink too much sugar and they have a break-through medicine that treats insulin resistance, for which, they just cleared up legal liabilities and gained the right to market their product to a broader spectrum of patients. I bought it close to a buck, just sold it to hold another position, will hold it again soon. This is a long-term pick IMO.

Recs

1
Member Avatar imagineimu (< 20) Submitted: 3/3/2007 9:11:07 AM : Outperform Start Price: $15.60 INSM Score: -86.95

This stock has been under pressure do to the on going litigation with trca/dna. Once this is over, which it appears it is close being it should increase substantially. INSM has orphan drug status and should get European market approval within the next 30 days and thus locking out any competitor for 10 years, it is also being tested for ALS uses by the Italian government and if positive results come out iplex could be the next billion dollar drug.

Recs

1
Member Avatar obiwankenobe1250 (80.31) Submitted: 3/3/2007 8:51:47 AM : Underperform Start Price: $15.60 INSM Score: +86.95

Voraciously consuming an inordinate amount of cash relative to its revenues. Long term prospects had better pan out, because the near term looks pretty dismal. And besides, downwithpumpers provided the tip.

Recs

1
Member Avatar theonlyslacker (80.31) Submitted: 3/2/2007 3:08:38 PM : Outperform Start Price: $15.70 INSM Score: -85.72

Have picked this stock since below a dollar. Company has numerous possible indications for their drugs in major categories. Price is risk weighted heavily as a result of financials and litigation with larger companies (DNA/TRCA). Two continuation in scheduled court dates lead one to speculate there is a settlement in the works. If you remove the cloud of litigation raising money should not be difficult assuming part of any settlement does not include capital.

Recs

0
Member Avatar mcob337 (< 20) Submitted: 2/22/2007 11:25:58 PM : Outperform Start Price: $15.00 INSM Score: -75.68

Letigation holding this winner down.

Recs

0
Member Avatar RBBioContest06 (66.58) Submitted: 5/31/2006 10:31:45 PM : Outperform Start Price: $16.50 INSM Score: -105.35

Picked by ferros

Recs

0
Member Avatar TMFStockPick06 (81.11) Submitted: 5/23/2006 5:36:19 PM : Outperform Start Price: $15.62 INSM Score: -101.07

This stock was picked by TMF Rael.

Results 1 - 13 of 13

Featured Broker Partners